What happens if we don’t rein in Big Tech now?

Morning Bullets header logo

Your daily source for trading strategies, tech news, and politically incorrect humor.

Hey there, Bullets Fans –

Your Morning Bullets Brief Updates are here! And that means trivia is, too.

On this day in the year 2000, the Dow saw the peak of its internet bubble. How high was it? 

Think you know the answer? You can check it in the closing area down below!

5 things you need to know before the market opens today

Image Source: Morning Bullets

Futures were mixed this morning. The Nasdaq reflected losses while the Dow Jones Industrial Average and the S&P 500 logged gains.

Today the Labor Department reported its latest look at jobless claims. Economists had expected new filings to come in around 800,000. Also today, Joe Biden will share the details of his stimulus relief plan. And Johnson & Johnson released encouraging data about its one-dose vaccine (more on that, below) that could potentially be granted emergency-use authorization here in the U.S.

Meanwhile, Senate Majority Leader Mitch McConnell said that President Donald Trump’s impeachment trial is slated to start next week, on Tuesday. The House voted 232-197 to impeach him.

And finally, Petco and Poshmark will make their big Nasdaq debut today.

What else should you know before the stock market opens this morning?

Other News That Matters To You:

Will you be protected from the Second Wave?


Recommended Link:
Click Here
When the governor of California saw the spike in COVID hospitalizations, he panicked.

He locked down nearly the entire state.

And he dealt a death blow to tens of thousands of businesses in the nation’s richest state.

Now, other states are sliding down the same path.
This is not just the second wave of the pandemic. It’s also the second wave of the pandemic depression.

The good news is that we have a way to help you protect your portfolio.


This new 'promising' vaccine is only one dose

Image Source: The Street

On the vaccine front, there was some good news from Johnson & Johnson yesterday. The company released data showing that their vaccine appears safe and produces promising results. This particular vaccine is especially notable in that it requires one dose instead of two.

In an early 805-person trial, many of the volunteers built up antibodies about a month after being inoculated, and everyone had those antibodies after about two months.

There were some side effects, which included fever and fatigue, as well as achiness.

Data from the phase three trial (which consists of 45,000 participants) is expected to be released before month’s end.

“We have three months stability as of this moment at 2 to 8 degrees Celsius [or 36 to 46 degrees Fahrenheit],” said Johnson & Johnson officer Dr. Paul Stoffels. “That will be expanded over the year as we generate more stability data.”

If everything goes well, when could we expect to see emergency use authorization?

More Headline You Need To Read:

Thanks for reading once again! And don’t worry, I didn’t forget:

Here’s where you can go to check your answer!

Know someone who should be getting these Bullet Briefs? Make sure to send them over to www.morningbullets.com to subscribe.

Your biggest fan,


Fredrick Frost

P.S.  How useful did you find today’s Morning Bullets? 

Not useful – 22.63%

It was ok – 13.13%

It was good – 38.79%

Very useful – 25.45%

Author: Fredrick Frost

Fedrick Frost is the Editor-in-Chief of Morning Bullets. He mainly writes about Politics, The Economy and breaking news. With over 35 years in jounralism he has been influential in helping the morning bullets newsletter readers be informed every morning.